CIT and Stemina Ink Deal in Europe | 2011-02-17
Stemina announces the recent strategic partnership between Stemina and CIT in Evreux, France.  Under this partnership, CIT will distribute Stemina’s assays in Europe leveraging CIT’s considerable reputation and expertise to bring Stemina’s cutting edge technology for predictive toxicology to the market.

Stem cell scientists stress need for continued support of human embryonic stem cell research | 2010-10-26
Concerned by election rhetoric that portrays adult stem cells as adequate substitutes for human embryonic stem cells, several leading scientists joined with a patient advocate and the founders of a growing biotechnology company Tuesday to set the record straight before voters head to the polls next week.

Stemina Receives $1 million Contract from NCI | 2010-09-30
Stemina received a 2 year $1 million contract to study biomarkers of cancer stem cells and is a Phase II continuation of the original Phase I work performed for NCI in 2008 and 2009.  This project will be conducted in collaboration with Mayo Clinic and the University of Wisconsin's McArdle Cancer Center.  Stemina will be adding to the set of biomarkers of cancer stem cells discovered during the Phase I project and looking for those biomarkers circulating in animals. The objective is to find these biomarkers in patients as a means to assess the level of cancer stem cells in the patient in response to treatment or for monitoring patients for recurrence.

Stemina CEO Responds to Stem Cell Ruling and Wisconsin State Joural Article | 2010-08-25
I wanted to take a minute to send you some accurate information about the facts as they relate to Stemina. Having worked on the legal and political aspects of this important technology since Dr. Thomson was the first to isolate hESC in 1998 at the University of Wisconsin while I served as General Counsel for the Wisconsin Alumni Research Foundation (WARF), my experience tells me that the ruling will be overturned. Already, appeals are being filed and I am confident that very quickly the preliminary injunction will be lifted so that federal funding can still be used on the approved lines - which Stemina uses exclusively - while things get sorted out in the courts and legislature.

Stemina and Pioneer Hi-Bred Sign Research Agreement | 2010-06-01
Under the collaboration, Stemina will use its proprietary metabolomics platform and expertise in discovery and validation of small molecules to identify biomarkers associated with specific plant traits.

Stemina Partners with Bristol-Myers Squibb | 2010-05-27
A partnership with Bristol-Myers Squibb Co. will use Stemina's products to evaluate whether drugs the New York pharmaceutical company is developing might be toxic to the heart.

Stemina Featured in GenomeWeb's Startup Focus | 2010-05-27
Leveraging one of the newer 'omics fields along with stem cell technology, start-up firm Stemina Biomarker Discovery is looking to accelerate its work at developing metabolomic biomarkers for drug screening and efficacy and the detection of diseases.

Stemina Paper Accepted for Publication | 2010-05-26
Toxicology and Applied Pharmacology accepted Stemina's manuscript entitled "Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics" for publication. Read the abstract at the link below:

Agilent Technologies Announces Collaboration with Stemina | 2010-05-24
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Agilent is providing a 1290 Infinity UHPLC system to separate stem cellular metabolites, coupled to a 6530 Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS) to identify those metabolites. Agilent also is providing Mass Profiler Professional software to help Stemina researchers interpret the complex data generated by metabolomics experiments.